Molecule Types
As a full-service clinical research organization,
Protheragen brings board-level therapeutic-area expertise to every program we run—spanning
oncology,
rare disease, cardiometabolic, neurological, immunological, and infectious conditions, among others. By pairing disease-specific medical and operational know-how with a global site network and an uncompromising commitment to GCP and data integrity, we help sponsors design trials that regulators trust and patients can access—accelerating assets from first-in-human through approval and beyond.
Introduction to Molecule Types
A molecule type—more often called a therapeutic modality—describes what a medicine fundamentally is: a synthetic small molecule, a peptide, a protein-based antibody or biologic, a living cell, a gene- or nucleic-acid construct, a vaccine, an engineered device, or an in vitro diagnostic. The modality is not a detail layered on top of the science; it dictates how the asset is discovered, manufactured, formulated, delivered, and regulated, and it shapes the entire clinical-development plan—from the assays that qualify drug product to the endpoints that define success. A small molecule and a CAR-T cell may target the same tumor, yet they are run as utterly different trials.
Modern pipelines rarely rest on a single modality. A given therapeutic area is now served by several at once: oncology pairs antibodies and small molecules with cell therapies and gene therapies; immunology and inflammation runs on antibodies, biologics, and biosimilars; metabolic and cardiovascular programs lean on small molecules and peptides; and precision medicine increasingly depends on diagnostic kits and medical devices. Explore the full set of areas we serve on our Therapeutic Areas pages, and the modality detail on each sub-page linked below.
Figure 1. The annual trend of approval for CTMPs, GTMPs, and TEPs worldwide. (Ramezankhani R, et al., 2020)
As the landscape shows, the frontier of drug development has moved well beyond the oral small molecule. Biologics and antibodies now dominate chronic and autoimmune indications; cell and gene therapies have become curative-minded options in rare disease and hematology; nucleic-acid and editing platforms are opening targets once considered undruggable; and devices and diagnostics sit at the center of precision and interventional trials. Choosing the modality is therefore a strategic decision that determines not only the science but the trial design, the site network, and the regulatory path—which is exactly why Protheragen staffs each modality with specialists rather than treating all assets as interchangeable.
Why Modality Depth Determines Outcomes
The difference between a program that reads out cleanly and one that stalls is rarely the target alone—it is operational fit with the modality. A small-molecule Phase I is a healthy-volunteer, PK-driven study; a cell-therapy Phase I is a heavily monitored, site-by-site evaluation with distinct potency, vein-to-vein, and cytokine-release management requirements. A partner who has run dozens of CAR-T programs designs an in vivo AAV-based gene-therapy protocol differently than one who has only run oral drugs, because they understand the manufacturing, logistics, and long-term safety arcs that ATMP regulators actually enforce.
Manufacturing and supply chain are where modality expertise most directly protects timelines. Peptides and antibodies demand validated, scalable bioprocess and cold-chain control; biosimilars require analytical and functional comparability programs; gene therapies hinge on vector release and identity testing; and vaccines live or die on campaign-scale fill-finish. Getting these specs right upstream prevents the costly mid-study corrections—and the failed batches—that erode both budget and credibility.
Regulatory strategy compounds the effect. A device submission follows a risk-classification path (US FDA Class I–III / EU MDR Class I–III with sub-rules) distinct from a drug IND or CTA; a companion diagnostic is co-developed under an FDA CDx or IVDR framework alongside its therapeutic; and advanced-therapy medicinal products—cell therapies, gene therapies, and tissue-engineered products—carry their own CMC, environmental, and long-term follow-up expectations (commonly a 15-year LTFU under FDA RMAT and EMA ATMP guidance). Protheragen assigns modality-specific medical monitors, laboratory leads, and regulatory strategists—not a generic project manager—so the plan reflects current precedent for that exact type of asset.
Our Services
As a full-service clinical research organization, Protheragen conducts trials across all nine molecule types listed below—from first-in-human and Phase I–IV studies through regulatory submission, comparability, and post-marketing research. Each type links to a dedicated page detailing the formats we support and the clinical-development capabilities we bring to it; choose any molecule type to open its sub-page, or follow the therapeutic-area links to see how a specific modality pairs with the right disease.
| Molecule Type |
Representative Classes |
| Small Molecule |
Kinase / protease / epigenetic modulators, receptor agonists & antagonists, ion-channel modulators, targeted protein degraders (PROTAC & molecular glue) |
| Therapeutic Peptide |
Hormonal / metabolic peptides (GLP-1 class), antimicrobial peptides, receptor agonists, peptide–drug conjugates (PDC) |
| Therapeutic Antibody |
Monoclonal, polyclonal, bispecific & multispecific, antibody fragment, antibody-drug conjugate (ADC), antibody-toxin conjugate (ATC) |
| Biosimilar |
mAb biosimilars, therapeutic-protein biosimilars (insulin, EPO, G-CSF), Fc-fusion biosimilars |
| Cell Therapy |
Immune cell therapy (TIL, CAR-T, TCR-T, NK, CIK, dendritic), stem & progenitor (HSC, MSC, iPSC-derived), autologous & allogeneic |
| Gene Therapy |
AAV / lentiviral / adenoviral vectors, non-viral (LNP), in vivo & ex vivo, CRISPR / base / prime editing |
| Vaccine |
Live-attenuated, inactivated, subunit / recombinant, mRNA (LNP), viral-vectored, conjugate, toxoid |
| Medical Devices |
Class I–III interventional (stents, catheters), implantable, monitoring, SaMD, combination products |
| Diagnostic Kit |
Immunoassay (ELISA / CLIA / LFIA), molecular (PCR / NGS), point-of-care, companion diagnostics (CDx) |
Detailed Modality Profiles
Each molecule type below opens into the formats and clinical considerations we support across its trials. Follow any heading to its dedicated sub-page for the full scope. The classification below mirrors the taxonomy used across our site so you can move cleanly from a high-level modality to a specific clinical program.
Low molecular-weight synthetic compounds (<≈900 Da) remain the backbone of pharmacotherapy thanks to oral bioavailability, predictable PK/PD, and straightforward chemical manufacturing. Modern programs are organized around mechanism of action and target class, which we mirror below:
| kinase inhibitors (Tyrosine / Serine–Threonine / Lipid), protease and phosphatase inhibitors, epigenetic modulators (HDAC, BET, DNMT, EZH2, PRMT5), and metabolic-enzyme inhibitors (IDH1/2, DHODH). |
- Receptor Ligands & Allosteric Modulators
agonists and antagonists of GPCR, nuclear hormone receptor, cytokine receptor, and receptor tyrosine kinase targets, including biased ligands and negative / positive allosteric modulators (NAM / PAM). |
- Ion-Channel & Transporter Modulators
Nav, Cav, Kv, and ligand-gated channel modulators; SGLT2, DAT, SERT, NET, and solute-carrier transporter inhibitors for cardiometabolic and CNS indications. |
- Targeted Protein Degraders
heterobifunctional PROTACs, molecular-glue degraders (IMiD / CELMoD scaffolds), AUTAC / LYTAC for extracellular targets, and covalent warhead designs. |
- Protein–Protein Interaction (PPI) Disruptors
α-helix mimetics, stapled peptides, macrocycles, and covalent PPI inhibitors targeting oncogenic and immune checkpoints. |
- Nucleic-Acid & RNA-Targeted Small Molecules
splicing modulators, RNA-degrading small molecules (RiboTAC), and targeted RNA-binding scaffolds for traditionally undruggable transcripts. |
Peptides bridge small molecules and biologics—larger and more selective than oral drugs, yet cheaper to make than full proteins. The site taxonomy groups our clinical programs by length, source, function, and modification strategy:
- Hormonal & Metabolic Peptides
insulin and insulin analogs, GLP-1 / GIP / glucagon multi-agonists, amylin analogs, parathyroid and calcitonin peptides, and growth-hormone–releasing peptides. |
- Cyclic & Stapled Peptides
head-to-tail or disulfide-cyclized scaffolds and stapled α-helical peptides for oral bioavailability and protease resistance, including PPI-targeting oncology candidates. |
- Cell-Penetrating & Targeting Peptides
TAT, penetratin, and arginine-rich delivery peptides used as carriers into tumors, CNS, and intracellular compartments. |
- Antimicrobial Peptides (AMPs)
defensins, cathelicidins, and synthetic AMP scaffolds for anti-infective, anti-biofilm, and ophthalmic applications. |
- Modified Peptides & Peptide Conjugates
PEGylated, lipidated, glycosylated, or Fc-fused peptides for half-life extension, plus peptide–drug conjugates (PDC), peptide–radio conjugates (PRC), and peptide–siRNA chimeras. |
- Vaccine & Immunomodulatory Peptides
synthetic long peptides (SLP) for cancer vaccines, epitope-mapping peptides, and immune-modulating peptides (checkpoint, tolerance-induction). |
|
|
Antibody therapeutics are the dominant engineered-biologic class in today’s pipeline. Protheragen conducts clinical trials across the full range of antibody formats; the taxonomy below follows the format families a sponsor typically brings to the clinic:
- Monoclonal Antibodies (mAb)
chimeric, humanized, and fully human mAbs in oncology, immunology & inflammation, ophthalmology, and infectious disease; first-in-human and Phase I–IV trials with the PK / immunogenicity and anti-drug-antibody monitoring these programs require. |
- Polyclonal Antibody Therapies
polyclonal preparations (e.g., anti-infective, anti-toxin, Rho(D) immune globulin) evaluated in early-phase safety and efficacy trials where batch-to-batch consistency is a key endpoint. |
| dual-targeting formats (e.g., CD3 × tumor antigen) whose trials demand step-up dosing, cytokine-release (CRS) and ICANS monitoring, and target-mediated toxicity management. |
trispecific and higher-order constructs, generally in first-in-human dose-escalation with combination-biology endpoints. |
- Antibody Fragments (Fab, scFv, single-domain / VHH)
short-half-life formats requiring adaptive trial designs and frequent sampling for exposure and tissue-penetration readouts. |
- Antibody–Drug Conjugates (ADC)
tumor-targeting antibodies linked to cytotoxic payloads; trials center on payload-driven toxicities (myelosuppression, ocular, pulmonary), exposure–safety modeling, and dose optimization. |
- Antibody–Toxin Conjugates (ATC / immunotoxins)
antibodies paired with biological toxins (pseudomonas exotoxin, diphtheria toxin) for hematologic and select solid-tumor indications; trials emphasize toxin-specific safety and immunogenicity monitoring. |
|
A biosimilar is a highly similar, later-entrant version of an approved reference biologic. We support biosimilarity programs across the reference-product categories below, with comparability, clinical-extrapolation, and interchangeable (US) / interchangeable-biosimilar (EU) studies where the sponsor pursues them:
- Monoclonal-Antibody (mAb) Biosimilars
reference products such as rituximab, trastuzumab, bevacizumab, adalimumab, infliximab, ranibizumab, denosumab, and ustekinumab; biosimilarity anchored on analytical and functional similarity. |
- Therapeutic-Protein Biosimilars
insulin and insulin-analog biosimilars, erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), somatropin (GH), and interferon products. |
- Fc-Fusion Protein Biosimilars
etanercept-class and other Fc-fusion constructs where glycosylation, half-life, and receptor binding are the critical comparability attributes. |
- Enzyme & Specialty Biosimilars
enzyme-replacement therapies (e.g., imiglucerase, agalsidase, velaglucerase) and select coagulation-factor biosimilars (factor VIII / IX) where orphan-disease trial design meets biosimilarity. |
- Interchangeability Programs (US-only designation)
switching / alternating studies designed to support an FDA §351(k)(6) interchangeable designation; only relevant to a subset of mAb / Fc-fusion programs. |
|
Living cells as therapeutics span autologous and allogeneic sources, immune-cell platforms, and stem and progenitor cells. Protheragen conducts clinical trials across the immune-cell therapy classes most active in oncology and related indications:
- Tumor-Infiltrating Lymphocyte (TIL) Therapy
autologous TIL expanded from resected tumor and reinfused after lymphodepletion; trials require leukapheresis, lymphodepletion, on-site cell-handling logistics, and CRS / ICANS monitoring. |
chimeric antigen receptor T cells against CD19, BCMA, and emerging solid-tumor targets; the most established ATMP class, with well-characterized CRS / ICANS management, long-term follow-up (LTFU), and risk-evaluation (REMS-type) dispensing paths. |
- TCR-engineered T-cell (TCR-T) Therapy
engineered receptors against intracellular tumor antigens presented on HLA; trials emphasize HLA-subtype selection, on-target / off-tumor toxicity, and target-organ monitoring. |
natural-killer and CAR-NK programs, including off-the-shelf allogeneic platforms; trials differ from CAR-T in reduced GvHD risk and distinct cytokine-release profiles. |
- Cytokine-Induced Killer (CIK) Cell Therapy
less HLA-restricted effector populations; typically evaluated in combination with standard therapy in early-phase studies. |
- Dendritic Cell (DC) Therapy / DC Vaccines
antigen-loaded dendritic cells and DC-based combination strategies; trials center on immunogenicity, antigen-specific T-cell responses, and vaccine-schedule optimization. |
Gene therapies correct, add, silence, or replace genetic material. We classify programs by delivery vehicle, route of administration, and whether the platform edits, supplements, or silences the target sequence:
- AAV-Based In Vivo Gene Therapy
single-stranded and self-complementary AAV across multiple serotypes (AAV1, 2, 5, 8, 9, rh10, AAVrh74) for CNS, retinal, neuromuscular, hepatic, and cardiac targets. |
- Lentiviral & Retroviral-Based Therapy
ex vivo modification of hematopoietic stem cells (HSC) and T cells; gamma-retroviral and lentiviral constructs used for CAR-T and inherited-hematology programs. |
- Non-Viral Delivery (LNP & Plasmid)
lipid nanoparticle–encapsulated mRNA, siRNA, and gene-editing cargos, plus electroporation of plasmid DNA for in vivo and ex vivo applications (vaccines, gene editing, protein replacement). |
- Gene Addition & Supplementation
one-time expression of a functional copy of a missing or mutated gene (SMN1, RPE65, Factor IX, dystrophin transgenes) for monogenic disorders. |
- Gene Silencing & RNA-Targeting
antisense oligonucleotides (ASO), siRNA, and shRNA approaches for allele-selective knockdown, gain-of-function suppression, and infectious-disease targets. |
CRISPR / Cas9, base editors (C-to-T / A-to-G / C-to-G), prime editing, zinc-finger nucleases, meganucleases, and epigenetic editors for in vivo and ex vivo correction of pathogenic variants. |
Vaccines have expanded from infectious disease into oncology and allergy. We support the major platforms below across prophylactic, therapeutic, and seasonal programs, with the immunogenicity, lot-consistency, and challenge (or surrogate) studies each platform demands:
| classical platforms (MMR, varicella, yellow fever, oral polio, BCG, intranasal influenza) where attenuation, shedding, and stability define the program. |
- Inactivated & Subunit / Recombinant Protein Vaccines
whole-inactivated virus, recombinant protein antigens (RBD, HA, gE), nano-particle / VLP scaffolds, and adjuvanted recombinant constructs (e.g., recombinant zoster, hepatitis B, HPV). |
| LNP-formulated mRNA and self-amplifying RNA platforms for infectious disease, oncology, and pan-respiratory combination antigens; cold-chain and immunogenicity-antisense requirements built in. |
replication-competent (VSV, measles, yellow fever) and replication-deficient (adenoviral / Ad26, ChAdOx1, AAV-vectored) constructs for prophylaxis and prime–boost combinations. |
- Conjugate, Toxoid & Polysaccharide Vaccines
CRM197 / tetanus-toxoid-conjugated polysaccharides (Hib, PCV13 / PCV15 / PCV20, MenACWY), standalone capsular polysaccharides, and toxoid antigens (tetanus, diphtheria). |
a use-case axis across the same platforms above: the mRNA, viral-vectored, peptide, DNA, and cell-based formats already listed are applied therapeutically—against cancer, chronic infection (HBV, HSV, HPV), and allergic or autoimmune disease—rather than only prophylactically. Cancer vaccines are the most active segment today, spanning peptide, RNA, DNA, virus-based, and cell-based formats applied therapeutically against tumors and chronic infection. |
Devices follow a risk-based regulatory path distinct from drugs. We structure our programs by US FDA class and EU MDR classification, by therapeutic specialty, and by the device–drug combination-product boundary:
- Class I / A Devices (low-risk)
non-invasive accessories, surgical instruments, and general well-established devices (sterile gauze, bandages, surgical tools); usually exempt from premarket notification but still under MDR general-safety and performance requirements. |
- Class II / B Devices (moderate-risk)
510(k) / EU MDR Class IIa devices including infusion pumps, ventilators, knee and hip implants, intra-ocular lenses, and most diagnostic electrophysiology hardware. |
- Class III / C Devices (high-risk)
PMA / EU MDR Class III devices: implantable defibrillators, heart valves, neuroprostheses, deep-brain stimulators, and other life-supporting or life-sustaining implants. |
- Software as a Medical Device (SaMD) & AI-Enabled Devices
standalone medical-imaging software, algorithm-driven triage and monitoring tools, and continuously-learning AI/ML devices subject to the FDA PCCP, EU AI Act, and IEC 62304 frameworks. |
- Combination Products (Drug-Device & Biologic-Device)
drug-eluting stents, prefilled syringes, intrathecal pumps, antibiotic-loaded bone cements, and combination-product approvals under the FDA OCP and EU MDR Article 117. |
- In Vitro Diagnostic & Imaging Hardware
IVR / IVDR diagnostic hardware that complements the diagnostic-kit sub-page, plus imaging modalities (CT, MR, PET, ultrasound, OCT) where device-performance and clinical-utility evidence are evaluated together. |
In vitro diagnostics (IVDs) enable precision medicine. We organize our diagnostic-kit clinical programs by analyte, technology, intended use, and setting, aligning with FDA LDT / 510(k) / PMA, EU IVDR risk class A–D, and the workflow of the therapeutic they may travel with:
| ELISA, chemiluminescent immunoassays (CLIA / CLEIA), electrochemiluminescence, and lateral-flow immunoassays (LFIA) for protein, hormone, and serology markers. |
- Molecular Diagnostics & Next-Generation Sequencing
qPCR, multiplex PCR, isothermal amplification (LAMP / NEAR / CRISPR-Dx), Sanger sequencing, NGS panels (targeted / whole-exome / whole-genome), and methylation-based assays. |
- Point-of-Care & Near-Patient Testing
rapid antigen, rapid molecular, and microfluidic cartridge platforms for clinic, emergency, and over-the-counter (OTC) use; tropical-disease, sexually-transmitted-infection, and cardiac-marker flagship programs. |
- Companion Diagnostics (CDx)
FDA CDx and EU IVDR CDx programs co-developed with a therapeutic, including bridging studies to a cleared device, multi-variate algorithmic IVDs, and NGS-based tumor profiling that selects for targeted therapy. |
- Tissue & Liquid-Biopsy Diagnostics
immunohistochemistry (IHC), in situ hybridization (ISH), circulating tumor DNA (ctDNA), circulating tumor cells (CTC), cell-free RNA, and exosome-based assays for oncology, NIPT, and transplant monitoring. |
- Self-Testing & Home-Use Diagnostics
OTC / self-collected sample kits (glucose, HbA1c, pregnancy / ovulation, FIT, HIV self-test, COVID antigen) where labeling studies and usability validation drive the clinical program. |
Selecting the Right Modality for Each Area
The platform is as area-specific as the endpoint. A small molecule may be the obvious fit for a cardiometabolic target, yet a therapeutic peptide such as a GLP-1 analog has reshaped metabolic care, and a therapeutic antibody remains the workhorse across immunology, dermatology, and oncology. Where an originator biologic has lost exclusivity, a biosimilar offers a faster, lower-risk path to the same population.
The frontier is increasingly biological and genetic. Cell therapies have transformed hematology and are expanding into autoimmune and solid tumors; gene therapies are curative-minded options in rare disease and neurology; and vaccines now extend beyond infection into oncology and allergy. Precision programs lean on diagnostic kits and medical devices for selection and delivery. Explore the full spectrum on our Therapeutic Areas pages, where each area links back to the modalities that serve it.
Contact Us
Ready to move your modality forward? Whether you need a single first-in-human study or a multi-modality global portfolio, Protheragen is ready to scope, quote, and run it end to end. Tell us your molecule type, target indications, and stage—our modality leads will return a tailored development plan and a transparent proposal, typically within two business days. Contact our team today to start the conversation and place your order with a partner built to deliver data you can defend.
Reference
- Ramezankhani R, et al. (2020) "Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies", Front Cell Dev Biol, 8:547653.